Frontiers in Cardiovascular Medicine

APRIL 5, 2024

The authors will elaborate on how the optimization of inhaled NO therapy, the development of biomarkers to identify the target population and the definition of response can improve the design of future large clinical trials.

Pediatrics 93

Pediatrics Pulmonary Biomarkers Innovation 93

DAIC

FEBRUARY 1, 2024

Elevated levels of two protein biomarkers that indicate heart damage were associated with undetected or symptomless cardiovascular disease in adults with Type 2 diabetes compared to those without Type 2 diabetes, according to new research published May 31, 2023, in the Journal of the American Heart Association, JAHA.

Cardiovascular Disease 104

Cardiovascular Disease Atherosclerosis Strokes Stroke 104

DAIC

MARCH 25, 2025

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

DAIC

SEPTEMBER 19, 2024

This achievement marks a significant milestone for Astellas as we integrate innovative technology with tailored patient support.” “The Digitiva is comprised of three components: the CORE 500 Digital Stethoscope developed by Eko Health Inc., a smartphone app designed for heart failure patients and built on the Welldoc, Inc.

Heart Failure 105

Heart Failure Technology Biomarkers Innovation 105

Cardiometabolic Health Congress

OCTOBER 25, 2024

The Hilton Boston Park Plaza became a hub of innovation, education, and collaboration, uniting nearly 500 clinicians under a shared mission: to redefine cardiometabolic care. The 19th Annual CMHC was more than just CME/CE medical education—it ignited global collaboration and inspired groundbreaking innovations.

CME 64

CME Innovation Education Atherosclerosis 64

Frontiers in Cardiovascular Medicine

JANUARY 2, 2024

Artificial intelligence (AI) has emerged as a promising field in cardiovascular disease (CVD) research, offering innovative approaches to enhance diagnosis, treatment, and patient outcomes. In this study, we conducted bibliometric analysis combined with topic modeling to provide a comprehensive overview of the AI research landscape in CVD.

Research 64

Research Cardiovascular Disease Biomarkers Innovation 64

DAIC

MAY 6, 2024

We are committed to protecting the future commercial value of our innovative PH-HFpEF treatment,” said Chris Giordano , President & Chief Executive Officer of Tenax Therapeutics. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

Journal of Clinical Investigation - Cardiology

MARCH 1, 2024

Future systematic evaluation of potential therapeutic approaches should evaluate consistency between human and animal pathophysiological mechanisms, utilize innovative clinical trial design from FXLEARN, and incorporate translatable biomarkers.

Research 45

Research Pharmacology Biomarkers Innovation 45

Circulation

JANUARY 15, 2024

These innovations may speed achieving the ultimate goal of providing noninvasively specific and clinically actionable information. Nevertheless, the relationship between CAC and the susceptibility of a plaque to provoke a thrombotic event remains incompletely understood. This review summarizes the current understanding and literature on CAC.

Coronary Artery Disease 45

Coronary Artery Disease Atherosclerosis Laboratory Plaque 45

GEMMS

MAY 22, 2024

In this article, we will explore the top 10 trends shaping the future of cardiovascular medicine, highlighting the innovative technologies and approaches that are revolutionizing the field. Innovative algorithms analyze gene biomarkers to provide predictive insights and personalized patient therapy.

Heart Disease 52

Heart Disease Blood Pressure Technology Innovation 52

Cardiometabolic Health Congress

AUGUST 8, 2024

We need a comprehensive and innovative approach to cardiorenal metabolic management and risk reduction to address this challenge. These interconnected diseases pose a significant global health threat, with cardiovascular diseases alone accounting for one-third of all deaths worldwide , according to the World Health Organization.

Education 59

Education Cardiovascular Disease Diabetes Kidney Disease 59

Cardiometabolic Health Congress

MARCH 8, 2024

Her research focuses on women’s cardiovascular health and cardio-obstetrics, cardiovascular risk prediction using coronary artery calcium scores and biomarkers, lipids, and cardiometabolic diseases. You can practically feel the energy and passion driving equal representation of women in medicine.

Cardiac Rehabilitation 59

Cardiac Rehabilitation Academic Diabetes Research 59

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Attendees, including hundreds of health professionals, gained access to the latest knowledge and developments in the field, from exclusive insights from one of the foremost authorities on atherosclerosis, Dr. Peter Libby, to innovations like new therapeutic agents and exciting advancements in renal protection.

CME 103

CME Obesity Heart Failure Biomarkers 103

Journal of Clinical Investigation - Cardiology

FEBRUARY 17, 2025

These findings highlight the role of CLN3 in GPD clearance and present an innovative method that will enable biomarker discovery and therapeutic advancement in lysosomal diseases.

Biomarkers 60

Biomarkers Innovation 60

Frontiers in Cardiovascular Medicine

JANUARY 13, 2025

Thus, it becomes imperative to uncover innovative approaches to facilitate the prompt identification and diagnosis of DCM. On the traditional clinical side, we tend to use serum biomarkers as well as imaging as the most common means of diagnosing diseases because of their convenience as well as affordability.

Cardiomyopathy 52

Cardiomyopathy Diabetes Research Biomarkers 52

Dr. Malcolm Kendrick

OCTOBER 30, 2024

(2022-25) Swiss Reinsurance Company: £645K China Kadoorie Biobank (2002-ongoing) AstraZeneca: $300K Bayer AG: £300K GlaxoSmithKline: £3.6M Elinogrel feasibility trial (2010-2011) Novartis: £500K EMPA-KIDNEY (2017-ongoing) Boehringer Ingelheim: £106.3M Establishing Fuwai-Oxford research centre (2010-ongoing) Merck: £1.1M

Cholesterol 145

Cholesterol Article Research Diet 145